CRISPR Therapeutics CRSP Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $423.31M+21.8% | $347.56M+21.3% | $286.5M+48.0% | $193.62M-17.7% | $235.18M-21.1% | ||
| $2.02B+24.0% | $1.63B-0.1% | $1.63B+6.7% | $1.53B-5.7% | $1.62B+0.9% | ||
| -$0— | $0— | $0— | $0— | $0-100% | ||
| $2.45B+23.3% | $1.99B+2.9% | $1.93B+11.3% | $1.73B-7.2% | $1.87B-3.6% | ||
| $112.18M-3.2% | $115.85M-4.1% | $120.83M-3.3% | $124.93M-3.5% | $129.43M-3.5% | ||
| $2.73B+20.3% | $2.27B+0.9% | $2.25B+10.6% | $2.03B-6.3% | $2.17B-3.4% | ||
| $13.65M+22.5% | $11.14M-5.6% | $11.8M+21.0% | $9.75M-25.3% | $13.06M-11.2% | ||
| $15.34M-2.7% | $15.77M+1,118% | $1.3M-39.2% | $2.13M-29.5% | $3.02M-21.4% | ||
| $136.29M-8.6% | $149.12M+25.4% | $118.96M+14.0% | $104.36M-12.6% | $119.45M+36.1% | ||
| —— | —— | —— | —— | —— | ||
| $911.26M+165% | $343.43M+4.3% | $329.33M+3.4% | $318.59M-5.4% | $336.94M+8.7% | ||
| $3.12M+0.9% | $3.09M+2.5% | $3.01M+7.8% | $2.79M+2.7% | $2.72M+0.9% | ||
| -$2.07B-6.3% | -$1.95B-7.2% | -$1.82B-6.2% | -$1.71B-13.9% | -$1.5B-10.0% | ||
| $1.81B-5.6% | $1.92B+0.3% | $1.92B+12.0% | $1.71B-6.5% | $1.83B-5.3% | ||
| $2.73B+20.3% | $2.27B+0.9% | $2.25B+10.6% | $2.03B-6.3% | $2.17B-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can CRISPR Therapeutics cover its short-term obligations?
- Its current ratio is 17.96 — current assets exceed current liabilities.
- Where does CRISPR Therapeutics's balance sheet data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.